CG Oncology (CGON) Stock: Buy, Sell, or Hold?
CGON - CG Oncology, Inc. Common stock
$62.38
-1.26 (-1.98%)
▼
5d:
-12.0%
30d:
-15.01%
90d:
-14.92%
WAIT
LOW Confidence
Analysis Updated: Oct 7, 2026 12:00 AM ET
Earnings: Nov 13, 2026
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Oct 6, 2026 at $63.64 · last confirmed Oct 7, 2026
Strength: 6.5/10
Get Alerted When CGON Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CGON is down 12.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CGON is down 12.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: CGON is currently trading at $62.38, which is considered oversold relative to its 30-day fair value range of $70.28 to $77.03.
Technical Outlook: Technically, CGON is in a uptrend. The price is currently testing key support at $61.90. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CGON scores 28/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $91.08 (+46.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CGON is in a uptrend. The price is currently testing key support at $61.90. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CGON scores 28/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $91.08 (+46.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$70.28 -
$77.03
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (28/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 46.0% below Wall St target ($91.08)
- WARNING: Composite score 52/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$70.28 -
$77.03
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$61.90
Resistance Level
$73.44
Current Trend
Uptrend
Technical data as of
Oct 7, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-20.65
Wall Street Target
$91.08
(+46.0%)
Revenue Growth (YoY)
1982.7%
Share & Embed Analysis
Last updated: October 07, 2026 7:52 PM ET
Data refreshes hourly during market hours. Next update: 8:52 PM
Data refreshes hourly during market hours. Next update: 8:52 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CGON showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
James Mulay
SELL
15600 shares
2026-04-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
22 analysts |
$109 | 76 BUY |
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
27 analysts |
$92 | 49 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$285 | 48 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 71 BUY |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$128 | 63 BUY |
